CTOs on the Move

MaxThera

www.maxthera.com

 
MaxThera, Inc. is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.maxthera.com
  • 100 Cummings Ctr Ste 419E
    Beverly, MA USA 01915
  • Phone: 978.927.8900

Executives

Name Title Contact Details

Similar Companies

BHE

BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.

Pharmaceutics International

Pharmaceutics International, Inc. (Pii) is a US-based contract development and manufacturing organization (CDMO) with a passion for solving problems. Pii`s Hunt Valley, Maryland, campus includes 70 manufacturing suites with four integrated aseptic filling lines. We offer contract analytical development and support formulation and manufacturing of oral solid dosage forms. Our professionals have extensive experience with small and large molecule compounds, developing and manufacturing complex parenteral drugs, extended-release formulations, non-aqueous injectable drug products, lyophilization, and DEA scheduled drugs.

Auburn Pharmaceutical

Auburn Pharmaceutical is a national full line generics wholesaler that purchases all of its products directly from 100+ manufacturers and is licensed across the Continental United States.

Emendo Biotherapeutics

Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.